Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
Lianluo Smart Limited is a professional smart service products provider, which dev...
Lianluo Smart Limited is a professional smart s...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...
ReWalk Robotics (Nasdaq: RWLK) is an innovative...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...
Protagonist Therapeutics is a clinical stage bi...
Join the National Investor Network and get the latest information with your interests in mind.